Shane Albright is a partner in the firm’s Life Sciences group. Mr. Albright represents life science and technology companies in a wide range of corporate, financial and commercial matters, with a particular emphasis on complex transactions involving intellectual property. He has extensive experience counseling clients on corporate partnering issues, strategic alliances, technology licenses and key commercial contracts, such as manufacturing and distribution agreements.

Mr. Albright regularly provides advice on licensing and commercial contract issues in connection with mergers and acquisitions, IPOs and other public financings. He also represents emerging growth companies and their investors in venture financings, other funding transactions and general corporate matters. Mr. Albright’s clients include companies in the biopharmaceutical, medical device, diagnostics, hardware, software, medical instrumentation, digital health, vaccine and research reagent spaces, as well as entities that fund or conduct medical research.

Prior to joining Goodwin in 2018, Mr. Albright was a partner at DLA Piper.

Areas of Practice
Domaines D’Expertise





Mr. Albright’s representative matters include:

  • A public pharmaceutical company in the negotiation of a series of territory-specific out-licenses for its erectile dysfunction drug*
  • A medical-device manufacturer in a collaboration agreement with a pharmaceutical company under which the parties will develop and commercialize new medicines based on the combination of the pharmaceutical company’s drugs with devices developed by the client*
  • A venture-backed company in a multimillion-dollar collaboration with a pharmaceutical company for development of an oral treatment for psoriasis*
  • A San Francisco-based research institute in multiple licenses and/or research collaborations with leading global pharmaceutical companies*
  • A biopharmaceutical company that focuses on creating treatments for rare diseases in its acquisition of worldwide rights to two drugs used in treating urea-cycle disorders*
  • Negotiated and drafted multiple agreements on behalf of a biomedical research consortium in connection with the launch of a ground-breaking multi-drug clinical trial*
  • A U.S. biotechnology company in the exclusive out-licensing of Japanese development and commercialization rights to the company’s oncology drug*
  • Assisted a U.S. biotechnology company in the formation of a global partnership with a pharmaceutical company focusing on the development and commercialization of the client’s DNA-based therapeutics*
  • Advised a startup biotechnology company in the outsourcing of research and development activities to an ex-U.S. research institute*
  • Advised a public life science company on the formation of a strategic alliance with a U.S. university*

* Denotes experience prior to joining Goodwin.


In recognition of his outstanding transactional work, Mr. Albright has been featured as a “Life Sciences Star” in LMG Life Sciences.

In The News









JD, 2002
Stanford Law School
(with distinction)
Ph.D., Molecular and Cell Biology, 1999
University of California, Berkeley
BS, Biological Sciences, 1991
Stanford University
(with distinction)



Profile Image
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.


Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Search Other Lawyers
Recherche par Pratique